Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group

British Journal of Cancer

Volumn 97, Issue 9, 2007, Pages 1200-1205

  Ray Coquard, I ^a   Paraiso, D ^b   Guastalla, J P ^a   Leduc, B ^c   Guichard, F ^d   Martin, C ^e   Chauvenet, L ^f   Haddad Guichard, Z ^g   Lepille D ^h   Orfeuvre, H ⁱ   Gautier, H ^j,k   Castera, D ^l   Pujade Lauraine, E ^f  

^a UNIVERSITÉ DE LYON   (France)

^b Centre Hospitalier de l'Agglomeration Montargeoise   (France)

^c CENTRE HOSPITALIER   (France)

^d Polyclinique Bordeaux Nord Aquitaine   (France)

^e Centre Hospitalier de la Region d'Annecy   (France)

^f HÔTEL DIEU   (France)

^g Centre Hospitalier Chalon sur Saone   (France)

^h CLINIQUE PASTEUR   (France)

ⁱ Hôpital Fleyriat   (France)

^j CMC de Bligny   (France)

^k Hopital Prive d'Antony   (France)

^l Clinique Saint Pierre   (France)

more..

Author keywords

Advanced ovarian cancer; Cyclophosphamide; Epirubicin; High dose chemotherapy; Randomised trial

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FARMORUBICINE; PLATINUM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, ENDOMETRIOID; CISPLATIN; CYCLOPHOSPHAMIDE; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 35648962356     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604026     Document Type: Article

References (19)

1. AOCT Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian cancer trialists group. BMJ 303: 884-893
2. Bookman MA, Greer BE, Ozols RF (2003) Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5. Int J Gynecol Cancer 13: 735-774
3. Buyse M, Burzykowski T, Parmar M, Torri V, Omura G, Colombo N, Williams C, Conte P, Vermorken J, International Collaborative Ovarian Neoplasm Collaborators (2003) Ovarian cancer meta-analysis project. Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer. J Clin Oncol 21: 1682-1687
4. Cure H, Battista RN, Guastalla J, Fabbro M, Tubiana N, Bourgeois H, Pujade-Lauraine E (2004) Phase III randomized trial of high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with advanced ovarian cancer (AOC): 5-year follow-up of a GINECO/FNCLCC/SFGM-TC study. J Clin Oncol, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 22: 14S [5006]
5. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS (1994) The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170: 974-979
6. International Collaborative Ovarian Neoplasm Group (1998) ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON collaborators. International collaborative ovarian neoplasm study. Lancet 352: 1571-1576
7. International Collaborative Ovarian Neoplasm Group (2002) Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360: 505-515
8. Kaplan ECMP (1958) Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 437-481
9. Ledermann JA, Frickhofen N, Wandt H, Bengala C, Champion KM, Hinke A, Moebus V (2005) A phase III randomised trial of sequential high dose chemotherapy (HDC) with peripheral blood stem cell support or standard dose chemotherapy (SDC) for first-line treatment of ovarian cancer. J Clin Oncol, 2205 ASCO Annual Meeting Proceedings 23: 16S [5006]
10. Levin L, Simon R, Hryniuk W (1993) Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. J Natl Cancer Inst 85: 1732-1742
11. Mantel NHW (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719-748
12. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6
13. Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR, Small JM (2000) Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18: 106-115
14. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, de Swart CA, Hirsch FR, Lund B, van Houwelingen HC (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18: 3084-3092
15. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol 21: 3194-3200
16. Ozols RF, Young RC (1991) Chemotherapy of ovarian cancer. Semin Oncol 18: 222-232
17. Perry MC (1992) Appendix-WHO toxicity guidelines. In The Chemotherapy Sources Book, Perry MC (ed) pp 1132-1144. Baltimore: Williams & Wilkins Inc
18. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699-708
19. Trimble EL, Arbuck SG, McGuire WP (1994) Options for primary chemotherapy of epithelial ovarian cancer: taxanes. Gynecol Oncol 55: S114-S121